Additionally, the 36-month beta value for BDSX is 0.98. There are mixed opinions on the stock, with 4 analysts rating it as a “buy,” 1 rating it as “overweight,” 1 rating it as “hold,” and 0 rating it as “sell.”
The public float for BDSX is 69.40M and currently, short sellers hold a 3.58% ratio of that float. The average trading volume of BDSX on June 10, 2025 was 8.28M shares.
BDSX) stock’s latest price update
Biodesix Inc (NASDAQ: BDSX)’s stock price has soared by 9.91 in relation to previous closing price of 0.29. Nevertheless, the company has seen a gain of 5.92% in its stock price over the last five trading days. globenewswire.com reported 2025-06-10 that Nation’s first CME-accredited course for APPs on clinical application of diagnostic biomarkers in Lung Nodule and Lung Cancer patient programs Nation’s first CME-accredited course for APPs on clinical application of diagnostic biomarkers in Lung Nodule and Lung Cancer patient programs
BDSX’s Market Performance
Biodesix Inc (BDSX) has experienced a 5.92% rise in stock performance for the past week, with a -14.32% drop in the past month, and a -60.99% drop in the past quarter. The volatility ratio for the week is 5.64%, and the volatility levels for the past 30 days are at 16.59% for BDSX. The simple moving average for the past 20 days is 3.01% for BDSX’s stock, with a -71.25% simple moving average for the past 200 days.
Analysts’ Opinion of BDSX
Craig Hallum gave a rating of “Buy” to BDSX, setting the target price at $3 in the report published on July 26th of the previous year.
BDSX Trading at -27.65% from the 50-Day Moving Average
After a stumble in the market that brought BDSX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -84.39% of loss for the given period.
#####
#####
Insider Trading
Reports are indicating that there were more than several insider trading activities at BDSX starting from SCHULER JACK W, who purchase 4,000,000 shares at the price of $0.27 back on May 16 ’25. After this action, SCHULER JACK W now owns 20,194,935 shares of Biodesix Inc, valued at $1,070,000 using the latest closing price.
SCHULER JACK W, the Director of Biodesix Inc, purchase 723,239 shares at $0.34 during a trade that took place back on May 19 ’25, which means that SCHULER JACK W is holding 20,918,174 shares at $246,624 based on the most recent closing price.
Stock Fundamentals for BDSX
Current profitability levels for the company are sitting at:
- -0.44 for the present operating margin
- 0.78 for the gross margin
The net margin for Biodesix Inc stands at -0.54. The total capital return value is set at -0.45. Equity return is now at value -1454.41, with -46.61 for asset returns.
Based on Biodesix Inc (BDSX), the company’s capital structure generated 0.85 points at debt to capital in total, while cash flow to debt ratio is standing at -0.67. The debt to equity ratio resting at 5.63. The interest coverage ratio of the stock is -4.39.
Currently, EBITDA for the company is -29.22 million with net debt to EBITDA at -1.63. When we switch over and look at the enterprise to sales, we see a ratio of 1.23. The receivables turnover for the company is 9.75for trailing twelve months and the total asset turnover is 0.86. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.22.
Conclusion
In conclusion, Biodesix Inc (BDSX) has seen bad performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
